Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome

10. februar 2014 opdateret af: Boehringer Ingelheim

RandomizEd Dabigatran Etexilate Dose Finding Study in Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors for Cardiovascular Complications Also Receiving Aspirin and Clopidogrel: Multi-centre, Prospective, Placebo Controlled, Cohort Dose Escalation Study (RE-DEEM)

The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4 doses of orally administered dabigatran etexilate, administered twice daily, compared to placebo when given in addition to dual antiplatelet treatment in patients with an index event (MI) at high risk for new ischaemic cardiovascular events.

Studieoversigt

Status

Afsluttet

Betingelser

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

1878

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Bouge/Namur, Belgien
        • 1160.67.32008 Boehringer Ingelheim Investigational Site
      • Brasschaat, Belgien
        • 1160.67.32011 Boehringer Ingelheim Investigational Site
      • Edegem, Belgien
        • 1160.67.32005 Boehringer Ingelheim Investigational Site
      • Genk, Belgien
        • 1160.67.32002 Boehringer Ingelheim Investigational Site
      • Gilly, Belgien
        • 1160.67.32006 Boehringer Ingelheim Investigational Site
      • Hasselt, Belgien
        • 1160.67.32003 Boehringer Ingelheim Investigational Site
      • Leuven, Belgien
        • 1160.67.32001 Boehringer Ingelheim Investigational Site
      • Tienen, Belgien
        • 1160.67.32004 Boehringer Ingelheim Investigational Site
      • Bourgas, Bulgarien
        • 1160.67.59007 Boehringer Ingelheim Investigational Site
      • Dimitrovgrad, Bulgarien
        • 1160.67.59009 Boehringer Ingelheim Investigational Site
      • Pleven, Bulgarien
        • 1160.67.59003 Boehringer Ingelheim Investigational Site
      • Pleven, Bulgarien
        • 1160.67.59012 Boehringer Ingelheim Investigational Site
      • Rousse, Bulgarien
        • 1160.67.59006 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgarien
        • 1160.67.59001 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgarien
        • 1160.67.59002 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgarien
        • 1160.67.59004 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgarien
        • 1160.67.59005 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgarien
        • 1160.67.59008 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgarien
        • 1160.67.59010 Boehringer Ingelheim Investigational Site
      • Quebec, Canada
        • 1160.67.11014 Boehringer Ingelheim Investigational Site
    • Alberta
      • Calgary, Alberta, Canada
        • 1160.67.11009 Boehringer Ingelheim Investigational Site
    • British Columbia
      • Vancouver, British Columbia, Canada
        • 1160.67.11003 Boehringer Ingelheim Investigational Site
    • Ontario
      • Cambridge, Ontario, Canada
        • 1160.67.11012 Boehringer Ingelheim Investigational Site
      • Hamilton, Ontario, Canada
        • 1160.67.11008 Boehringer Ingelheim Investigational Site
      • London, Ontario, Canada
        • 1160.67.11018 Boehringer Ingelheim Investigational Site
      • Mississauga, Ontario, Canada
        • 1160.67.11017 Boehringer Ingelheim Investigational Site
      • Sudbury, Ontario, Canada
        • 1160.67.11010 Boehringer Ingelheim Investigational Site
      • Sudbury, Ontario, Canada
        • 1160.67.11020 Boehringer Ingelheim Investigational Site
    • Quebec
      • Montreal, Quebec, Canada
        • 1160.67.11004 Boehringer Ingelheim Investigational Site
      • Montreal, Quebec, Canada
        • 1160.67.11016 Boehringer Ingelheim Investigational Site
      • Terrebonne, Quebec, Canada
        • 1160.67.11006 Boehringer Ingelheim Investigational Site
      • Aarhus C, Danmark
        • 1160.67.45001 Boehringer Ingelheim Investigational Site
      • Hvidovre, Danmark
        • 1160.67.45003 Boehringer Ingelheim Investigational Site
      • Odense, Danmark
        • 1160.67.45002 Boehringer Ingelheim Investigational Site
      • Roskilde, Danmark
        • 1160.67.45004 Boehringer Ingelheim Investigational Site
      • Moscow, Den Russiske Føderation
        • 1160.67.70001 Boehringer Ingelheim Investigational Site
      • Moscow, Den Russiske Føderation
        • 1160.67.70002 Boehringer Ingelheim Investigational Site
      • Moscow, Den Russiske Føderation
        • 1160.67.70003 Boehringer Ingelheim Investigational Site
      • Moscow, Den Russiske Føderation
        • 1160.67.70004 Boehringer Ingelheim Investigational Site
      • Moscow, Den Russiske Føderation
        • 1160.67.70005 Boehringer Ingelheim Investigational Site
      • Moscow, Den Russiske Føderation
        • 1160.67.70006 Boehringer Ingelheim Investigational Site
      • Moscow, Den Russiske Føderation
        • 1160.67.70007 Boehringer Ingelheim Investigational Site
      • Saratov, Den Russiske Føderation
        • 1160.67.70010 Boehringer Ingelheim Investigational Site
      • Saratov, Den Russiske Føderation
        • 1160.67.70011 Boehringer Ingelheim Investigational Site
      • St. Petersburg, Den Russiske Føderation
        • 1160.67.70008 Boehringer Ingelheim Investigational Site
      • St. Petersburg, Den Russiske Føderation
        • 1160.67.70009 Boehringer Ingelheim Investigational Site
      • Brighton, Det Forenede Kongerige
        • 1160.67.44003 Boehringer Ingelheim Investigational Site
      • Exeter, Det Forenede Kongerige
        • 1160.67.44002 Boehringer Ingelheim Investigational Site
      • Middlesbrough, Det Forenede Kongerige
        • 1160.67.44001 Boehringer Ingelheim Investigational Site
      • HUS, Finland
        • 1160.67.58001 Boehringer Ingelheim Investigational Site
      • Jyväskylä, Finland
        • 1160.67.58004 Boehringer Ingelheim Investigational Site
      • Kuopio, Finland
        • 1160.67.58003 Boehringer Ingelheim Investigational Site
      • Pori, Finland
        • 1160.67.58002 Boehringer Ingelheim Investigational Site
    • Florida
      • Clearwater, Florida, Forenede Stater
        • 1160.67.10002 Boehringer Ingelheim Investigational Site
      • Brest Cedex, Frankrig
        • 1160.67.3305A Boehringer Ingelheim Investigational Site
      • Brest Cedex, Frankrig
        • 1160.67.3305B Boehringer Ingelheim Investigational Site
      • Dijon Cedex, Frankrig
        • 1160.67.3303A Boehringer Ingelheim Investigational Site
      • Dijon Cedex, Frankrig
        • 1160.67.3303B Boehringer Ingelheim Investigational Site
      • Dijon Cedex, Frankrig
        • 1160.67.3303C Boehringer Ingelheim Investigational Site
      • Dijon Cedex, Frankrig
        • 1160.67.3303D Boehringer Ingelheim Investigational Site
      • Paris, Frankrig
        • 1160.67.3301A Boehringer Ingelheim Investigational Site
      • Tbilisi, Georgien
        • 1160.67.95001 Boehringer Ingelheim Investigational Site
      • Tbilisi, Georgien
        • 1160.67.95002 Boehringer Ingelheim Investigational Site
      • Tbilisi, Georgien
        • 1160.67.95003 Boehringer Ingelheim Investigational Site
      • Tbilisi, Georgien
        • 1160.67.95004 Boehringer Ingelheim Investigational Site
      • Tbilisi, Georgien
        • 1160.67.95005 Boehringer Ingelheim Investigational Site
      • Tbilisi, Georgien
        • 1160.67.95006 Boehringer Ingelheim Investigational Site
      • Amsterdam, Holland
        • 1160.67.31001 Boehringer Ingelheim Investigational Site
      • Den Bosch, Holland
        • 1160.67.31003 Boehringer Ingelheim Investigational Site
      • Den Haag, Holland
        • 1160.67.31007 Boehringer Ingelheim Investigational Site
      • Ede, Holland
        • 1160.67.31009 Boehringer Ingelheim Investigational Site
      • Groningen, Holland
        • 1160.67.31002 Boehringer Ingelheim Investigational Site
      • Helmond, Holland
        • 1160.67.31006 Boehringer Ingelheim Investigational Site
      • Hoogeveen, Holland
        • 1160.67.31011 Boehringer Ingelheim Investigational Site
      • Rotterdam, Holland
        • 1160.67.31005 Boehringer Ingelheim Investigational Site
      • Spijkenisse, Holland
        • 1160.67.31008 Boehringer Ingelheim Investigational Site
      • Tilburg, Holland
        • 1160.67.31004 Boehringer Ingelheim Investigational Site
      • Amedabad, Indien
        • 1160.67.91004 Boehringer Ingelheim Investigational Site
      • Chennai, Indien
        • 1160.67.91001 Boehringer Ingelheim Investigational Site
      • Hyderabad, Indien
        • 1160.67.91005 Boehringer Ingelheim Investigational Site
      • Lucknow, Indien
        • 1160.67.91007 Boehringer Ingelheim Investigational Site
      • Mumbai, Indien
        • 1160.67.91002 Boehringer Ingelheim Investigational Site
      • Pune, Indien
        • 1160.67.91003 Boehringer Ingelheim Investigational Site
      • Pune, Indien
        • 1160.67.91006 Boehringer Ingelheim Investigational Site
      • Dublin, Irland
        • 1160.67.53001 Boehringer Ingelheim Investigational Site
      • Dublin, Irland
        • 1160.67.53002 Boehringer Ingelheim Investigational Site
      • Ascoli Piceno, Italien
        • 1160.67.39006 Boehringer Ingelheim Investigational Site
      • Milano, Italien
        • 1160.67.39003 Boehringer Ingelheim Investigational Site
      • Milano, Italien
        • 1160.67.39005 Boehringer Ingelheim Investigational Site
      • Parma, Italien
        • 1160.67.39001 Boehringer Ingelheim Investigational Site
      • S. Maria Capua Vetere (CE), Italien
        • 1160.67.39002 Boehringer Ingelheim Investigational Site
      • Torino, Italien
        • 1160.67.39004 Boehringer Ingelheim Investigational Site
      • Busan, Korea, Republikken
        • 1160.67.82010 Boehringer Ingelheim Investigational Site
      • Daegu, Korea, Republikken
        • 1160.67.82008 Boehringer Ingelheim Investigational Site
      • Daegu, Korea, Republikken
        • 1160.67.82009 Boehringer Ingelheim Investigational Site
      • Daejeon, Korea, Republikken
        • 1160.67.82013 Boehringer Ingelheim Investigational Site
      • Daejoen, Korea, Republikken
        • 1160.67.82006 Boehringer Ingelheim Investigational Site
      • Incheon, Korea, Republikken
        • 1160.67.82007 Boehringer Ingelheim Investigational Site
      • Jeonju, Korea, Republikken
        • 1160.67.82012 Boehringer Ingelheim Investigational Site
      • Kwang-Ju, Korea, Republikken
        • 1160.67.82005 Boehringer Ingelheim Investigational Site
      • Pusan, Korea, Republikken
        • 1160.67.82011 Boehringer Ingelheim Investigational Site
      • Seoul, Korea, Republikken
        • 1160.67.82001 Boehringer Ingelheim Investigational Site
      • Seoul, Korea, Republikken
        • 1160.67.82002 Boehringer Ingelheim Investigational Site
      • Seoul, Korea, Republikken
        • 1160.67.82003 Boehringer Ingelheim Investigational Site
      • Seoul, Korea, Republikken
        • 1160.67.82004 Boehringer Ingelheim Investigational Site
      • Drammen, Norge
        • 1160.67.47005 Boehringer Ingelheim Investigational Site
      • Hamar, Norge
        • 1160.67.47002 Boehringer Ingelheim Investigational Site
      • Haugesund, Norge
        • 1160.67.47003 Boehringer Ingelheim Investigational Site
      • Hønefoss, Norge
        • 1160.67.47004 Boehringer Ingelheim Investigational Site
      • Oslo, Norge
        • 1160.67.47001 Boehringer Ingelheim Investigational Site
      • Bydgoszcz, Polen
        • 1160.67.48003 Boehringer Ingelheim Investigational Site
      • Bydgoszcz, Polen
        • 1160.67.48006 Boehringer Ingelheim Investigational Site
      • Gdynia, Polen
        • 1160.67.48004 Boehringer Ingelheim Investigational Site
      • Inowroclaw, Polen
        • 1160.67.48005 Boehringer Ingelheim Investigational Site
      • Sopot, Polen
        • 1160.67.48002 Boehringer Ingelheim Investigational Site
      • Warsaw, Polen
        • 1160.67.48001 Boehringer Ingelheim Investigational Site
      • Baia Mare, Rumænien
        • 1160.67.40006 Boehringer Ingelheim Investigational Site
      • Braila, Rumænien
        • 1160.67.40005 Boehringer Ingelheim Investigational Site
      • Bucharest, Rumænien
        • 1160.67.40001 Boehringer Ingelheim Investigational Site
      • Bucharest, Rumænien
        • 1160.67.40003 Boehringer Ingelheim Investigational Site
      • Bucharest, Rumænien
        • 1160.67.40004 Boehringer Ingelheim Investigational Site
      • Oradea, Rumænien
        • 1160.67.40002 Boehringer Ingelheim Investigational Site
      • Tg. Mures, Rumænien
        • 1160.67.40007 Boehringer Ingelheim Investigational Site
      • Barcelona, Spanien
        • 1160.67.34001 Boehringer Ingelheim Investigational Site
      • Barcelona, Spanien
        • 1160.67.34002 Boehringer Ingelheim Investigational Site
      • Madrid, Spanien
        • 1160.67.34005 Boehringer Ingelheim Investigational Site
      • Madrid, Spanien
        • 1160.67.34006 Boehringer Ingelheim Investigational Site
      • Sabadell (Barcelona), Spanien
        • 1160.67.34003 Boehringer Ingelheim Investigational Site
      • Tarragona, Spanien
        • 1160.67.34004 Boehringer Ingelheim Investigational Site
      • Göteborg, Sverige
        • 1160.67.46004 Boehringer Ingelheim Investigational Site
      • Göteborg, Sverige
        • 1160.67.46006 Boehringer Ingelheim Investigational Site
      • Malmö, Sverige
        • 1160.67.46007 Boehringer Ingelheim Investigational Site
      • Motala, Sverige
        • 1160.67.46005 Boehringer Ingelheim Investigational Site
      • Stockholm, Sverige
        • 1160.67.46002 Boehringer Ingelheim Investigational Site
      • Uppsala, Sverige
        • 1160.67.46001 Boehringer Ingelheim Investigational Site
      • Vaesteraas, Sverige
        • 1160.67.46003 Boehringer Ingelheim Investigational Site
      • Hradec Kralove, Tjekkiet
        • 1160.67.42007 Boehringer Ingelheim Investigational Site
      • Litomerice, Tjekkiet
        • 1160.67.42005 Boehringer Ingelheim Investigational Site
      • Ostrava, Tjekkiet
        • 1160.67.42008 Boehringer Ingelheim Investigational Site
      • Prague, Tjekkiet
        • 1160.67.42001 Boehringer Ingelheim Investigational Site
      • Teplice, Tjekkiet
        • 1160.67.42003 Boehringer Ingelheim Investigational Site
      • Zlin, Tjekkiet
        • 1160.67.42002 Boehringer Ingelheim Investigational Site
      • Berlin, Tyskland
        • 1160.67.49001 Boehringer Ingelheim Investigational Site
      • Berlin, Tyskland
        • 1160.67.49007 Boehringer Ingelheim Investigational Site
      • Dresden, Tyskland
        • 1160.67.49017 Boehringer Ingelheim Investigational Site
      • Hannover, Tyskland
        • 1160.67.49006 Boehringer Ingelheim Investigational Site
      • Homburg/Saar, Tyskland
        • 1160.67.49019 Boehringer Ingelheim Investigational Site
      • Ludwigshafen am Rhein, Tyskland
        • 1160.67.49008 Boehringer Ingelheim Investigational Site
      • Neuss, Tyskland
        • 1160.67.49015 Boehringer Ingelheim Investigational Site
      • Rostock, Tyskland
        • 1160.67.49004 Boehringer Ingelheim Investigational Site
      • Ivano-Frankovsk, Ukraine
        • 1160.67.38002 Boehringer Ingelheim Investigational Site
      • Kharkov, Ukraine
        • 1160.67.38004 Boehringer Ingelheim Investigational Site
      • Kharkov, Ukraine
        • 1160.67.38007 Boehringer Ingelheim Investigational Site
      • Kiev, Ukraine
        • 1160.67.38001 Boehringer Ingelheim Investigational Site
      • Kiev, Ukraine
        • 1160.67.38003 Boehringer Ingelheim Investigational Site
      • Kiev, Ukraine
        • 1160.67.38005 Boehringer Ingelheim Investigational Site
      • Nikolayev, Ukraine
        • 1160.67.38008 Boehringer Ingelheim Investigational Site
      • Odessa, Ukraine
        • 1160.67.38006 Boehringer Ingelheim Investigational Site
      • Budapest, Ungarn
        • 1160.67.36001 Boehringer Ingelheim Investigational Site
      • Budapest, Ungarn
        • 1160.67.36003 Boehringer Ingelheim Investigational Site
      • Budapest, Ungarn
        • 1160.67.36004 Boehringer Ingelheim Investigational Site
      • Debrecen, Ungarn
        • 1160.67.36002 Boehringer Ingelheim Investigational Site
      • Kecskemet, Ungarn
        • 1160.67.36007 Boehringer Ingelheim Investigational Site
      • Komarom, Ungarn
        • 1160.67.36006 Boehringer Ingelheim Investigational Site
      • Miskolc, Ungarn
        • 1160.67.36008 Boehringer Ingelheim Investigational Site
      • Mosonmagyarovar, Ungarn
        • 1160.67.36009 Boehringer Ingelheim Investigational Site
      • Zalaegerszeg, Ungarn
        • 1160.67.36005 Boehringer Ingelheim Investigational Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion criteria Patients with acute coronary syndromes with at least one additional risk factor for cardiovascular complications.

Exclusion criteria

  1. Long term treatment with any other oral anticoagulant
  2. Severe/disabling stroke within last 6 months
  3. Conditions associated with increased bleeding risk
  4. Anaemia or thrombocytopenia
  5. Severe renal impairment
  6. Liver disease
  7. Positive pregnancy test

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: placebo
matchet placebo
matchet placebo
Eksperimentel: Dabigatran etexilate 50mg
twice daily dosing,
capsules, twice daily, 26 weeks treatment
Eksperimentel: Dabigatran etexilate 75mg
twice daily dosing, patients with moderate renal impairment allocated 50mg bid
capsules, twice daily, 26 weeks treatment
Eksperimentel: Dabigatran etexilate 110mg
twice daily dosing, patients with moderate renal impairment allocated 75mg bid
capsules, twice daily, 26 weeks treatment
Eksperimentel: dabigatran etexilate 150mg
twice daily dosing, patients with moderate renal impairment allocated 110mg bid
capsules, twice daily, 26 weeks treatment

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Participants Displaying the Composite of Major and Clinically Relevant Minor Bleeding Events During Total Observation Time
Tidsramme: 6 month treatment period + 2 week post treatment follow up

International Society Thrombosis and Haemostasis (ISTH) definition of a major bleed, and clinically relevant minor bleed.

A bleeding event was considered as major if it was fatal, was a symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome), or caused a fall in haemoglobin level of ≥2 g/dL (≥1.24 mmol/L), or led to transfusion of ≥2 units of whole blood or red cells.

All non major bleeding events were classified as minor bleeds; minor bleeds were subdivided in clinically relevant minor bleeds and not clinically relevant minor bleeds. A CRBE was defined as an acute or subacute clinically overt bleed that did not meet the criteria of a major bleed but either lead to hospital admission and/or a physician guided medical or surgical treatment and/or a change in antithrombotic therapy (including interruption or discontinuation of study drug).

6 month treatment period + 2 week post treatment follow up

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Composite of Cardiovascular Death (CVD) With Non Fatal Myocardial Infarction (MI) and Non Haemorrhagic Stroke and All Cause Death (ACD), Non Fatal MI, Severe Recurrent Ischaemia (SRI) and Non Haemorrhagic Stroke During Six Months Treatment
Tidsramme: 6 month treatment period + 2 week post treatment follow up
Number of Participants with Composite of Cardiovascular death (CVD) with non fatal myocardial infarction (MI) and non haemorrhagic stroke and All cause death (ACD), non fatal MI, severe recurrent ischaemia (SRI) and non haemorrhagic stroke during six months treatment
6 month treatment period + 2 week post treatment follow up
Individual Occurrence of Death (Cardiovascular and All-cause), Non-fatal MI, Severe Recurrent Ischaemia and Non-haemorrhagic Stroke During Six Months of Treatment
Tidsramme: 6 month treatment period + 2 week post treatment follow up
Number of Participants with individual occurrence of death (cardiovascular and all-cause), non-fatal MI, severe recurrent ischaemia and non-haemorrhagic stroke during six months of treatment.
6 month treatment period + 2 week post treatment follow up
Number of Participants With Any Reduction of D-dimer Concentration
Tidsramme: at 1 week and 4 weeks
at 1 week and 4 weeks
Change From Baseline in log10 D-dimer After 1 and 4 Weeks
Tidsramme: Baseline and at 1 week and 4 weeks
Change from baseline in log10 D-dimer concentration after 1 and 4 weeks of dabigatran etexilate treatment compared to placebo. The standard deviation is the geometric standard deviation.
Baseline and at 1 week and 4 weeks
Number of Participants With Bleeding Events During Total Observation Time
Tidsramme: 6 month treatment period + 2 week post treatment follow up

International Society Thrombosis and Haemostasis (ISTH) definition of a major bleed, and clinically relevant minor bleed.

A bleeding event was considered as major if it was fatal, was a symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome), or caused a fall in haemoglobin level of ≥2 g/dL (≥1.24 mmol/L), or led to transfusion of ≥2 units of whole blood or red cells.

All non major bleeding events were classified as minor bleeds; minor bleeds were subdivided in clinically relevant minor bleeds (CRBE) and not clinically relevant minor bleeds. A CRBE was defined as an acute or subacute clinically overt bleed that did not meet the criteria of a major bleed but either lead to hospital admission and/or a physician guided medical or surgical treatment and/or a change in antithrombotic therapy (including interruption or discontinuation of study drug).

6 month treatment period + 2 week post treatment follow up
Laboratory Analyses
Tidsramme: 6 month treatment period + 2 week post treatment follow up
Number of patients with possible clinically significant abnormalities. Clinically significant abnormalities refers to the increase or decrease from baseline.
6 month treatment period + 2 week post treatment follow up

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. marts 2008

Primær færdiggørelse (Faktiske)

1. oktober 2009

Datoer for studieregistrering

Først indsendt

13. februar 2008

Først indsendt, der opfyldte QC-kriterier

21. februar 2008

Først opslået (Skøn)

22. februar 2008

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

12. marts 2014

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. februar 2014

Sidst verificeret

1. februar 2014

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 1160.67
  • RE-DEEM (Anden identifikator: OTHER)
  • 2007-004301-99 (EudraCT nummer: EudraCT)

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner